Developing new antifungal treatments for resistant mould infections
Optimization and chemical biology of novel antifungals to combat azole resistant mould infections
This study is working on new antifungal medicines to help people with tough mould infections that don’t respond to current treatments, especially for those caused by a common fungus called Aspergillus fumigatus.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dartmouth College NIH-funded |
| Lab location | 1 site (Hanover, United States) |
| Project ID | NIH-11061824 on NIH RePORTER |
What this research studies
This research focuses on creating new antifungal medications to effectively treat infections caused by moulds, particularly those resistant to current treatments. The team is developing a series of small molecules that have shown promise in laboratory tests for overcoming drug resistance in common pathogens like Aspergillus fumigatus. By utilizing advanced screening techniques, they aim to identify compounds that work well even in challenging conditions, such as low oxygen environments. The goal is to provide better treatment options for patients suffering from severe fungal infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suffering from infections caused by azole-resistant moulds, particularly those with Aspergillus fumigatus.
Not a fit: Patients with fungal infections that are not caused by moulds or those who do not have azole-resistant strains may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective antifungal treatments for patients with resistant mould infections, improving their chances of recovery.
How similar studies have performed: Other research has shown promise in developing new antifungal agents, but this specific approach targeting azole-resistant moulds is relatively novel.
Where this research is happening
Hanover, United States
- Dartmouth College — Hanover, United States (Active)
Researchers
- Principal investigator: Cramer, Robert Andrew — Dartmouth College
- Study coordinator: Cramer, Robert Andrew
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.